PRME:ARCA-First Trust Heitman Global Prime Real Estate (USD)

ETF | Biotechnology | NYSE Arca

Last Closing

USD 6.76

Change

+0.10 (+1.50)%

Market Cap

USD 0.96M

Volume

0.70M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

The investment seeks to provide long-term total return. Under normal market conditions, the fund will seek to achieve its investment objective by investing at least 80% of its net assets (including investment borrowings) in U.S. and non-U.S. exchange-traded real estate securities, which includes real estate investment trusts ("REITs"), real estate operating companies ("REOCs") and common stocks or depositary receipts of companies primarily engaged in the real estate industry (collectively, "RealEstate Securities"). It is non-diversified.

Inception Date: 11/11/2015

Primary Benchmark: FTSE EPRA Nareit Developed TR USD

Primary Index: MSCI ACWI NR USD

Gross Expense Ratio: NA%

Management Expense Ratio: 0.95 %

Unadjusted Closing Price

Adjusted Closing Price

Assets

N/A

Top Holdings

N/A

Top Sectors

N/A

Top Regions

N/A

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-03-27 )

Largest Industry Peers for Biotechnology

Symbol Name Mer Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc 0.00 %

-0.22 (-0.06%)

USD 107.38B
REGN Regeneron Pharmaceuticals Inc 0.00 %

-7.48 (-0.84%)

USD 106.98B
MRNA Moderna Inc 0.00 %

+1.79 (+1.69%)

USD 38.83B
ARGX argenx NV ADR 0.00 %

+4.20 (+1.14%)

USD 22.08B
BNTX BioNTech SE 0.00 %

+0.50 (+0.58%)

USD 21.93B
GMAB Genmab AS 0.00 %

+0.69 (+2.51%)

USD 19.78B
ALNY Alnylam Pharmaceuticals Inc 0.00 %

-0.40 (-0.28%)

USD 18.18B
RPRX Royalty Pharma Plc 0.00 %

-0.11 (-0.39%)

USD 18.18B
BGNE BeiGene Ltd 0.00 %

+5.02 (+3.38%)

USD 16.99B
BMRN Biomarin Pharmaceutical Inc 0.00 %

-1.26 (-1.53%)

USD 16.06B

ETFs Containing PRME

XDNA 5.77 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (NYSE Arca)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -23.70% 21% F 18% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -23.70% 21% F 17% F
Trailing 12 Months  
Capital Gain -46.05% 31% F 20% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -46.05% 31% F 20% F
Trailing 5 Years  
Capital Gain -67.66% 47% F 19% F
Dividend Return 0.96% 17% F 4% F
Total Return -66.71% 48% F 19% F
Average Annual (5 Year Horizon)  
Capital Gain -12.72% 44% F 25% F
Dividend Return -12.67% 44% F 24% F
Total Return 0.05% 11% F 3% F
Risk Return Profile  
Volatility (Standard Deviation) 20.24% 97% N/A 76% C+
Risk Adjusted Return -62.60% 27% F 17% F
Market Capitalization 0.96M 79% B- 71% C-

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector